Interleukin-6 levels as an evolution marker of late mortality and cardiovascular events after an episode of community-acquired pneumonia.

S. Luquero Bueno (Madrid, Spain), J. Galván-Román (Madrid, Spain), J. Curbelo (Madrid, Spain), M. Ortega-Gómez (Madrid, Spain), Á. Lancho-Sánchez (Madrid, Spain), L. Vega-Piris (Madrid, Spain), M. Gómez (Madrid, Spain), H. De La Fuente (Madrid, Spain), C. Suárez (Madrid, Spain), L. Jiménez-Borreguero (Madrid, Spain), J. Aspa Marco (Madrid, Spain)

Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Session: Predicting the future: biomarkers of respiratory infection
Session type: Thematic Poster
Number: 2606
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Luquero Bueno (Madrid, Spain), J. Galván-Román (Madrid, Spain), J. Curbelo (Madrid, Spain), M. Ortega-Gómez (Madrid, Spain), Á. Lancho-Sánchez (Madrid, Spain), L. Vega-Piris (Madrid, Spain), M. Gómez (Madrid, Spain), H. De La Fuente (Madrid, Spain), C. Suárez (Madrid, Spain), L. Jiménez-Borreguero (Madrid, Spain), J. Aspa Marco (Madrid, Spain). Interleukin-6 levels as an evolution marker of late mortality and cardiovascular events after an episode of community-acquired pneumonia.. 2606

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Platelet count as an evolution marker of late mortality and cardiovascular events after an episode of community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019

Incidence, risk factors and outcomes of cardiovascular events in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus
Year: 2009

Management-based risk prediction in community-acquired pneumonia by scores and biomarkers
Source: Eur Respir J 2013; 41: 974-984
Year: 2013



Is community-acquired pneumonia an independent risk factor for cardiovascular disease?
Source: Eur Respir J 2011; 39: 187-196
Year: 2012



Is community-acquired pneumonia an independent risk factor for cardiovascular disease?
Source: Eur Respir J 2012; 39: 187-196
Year: 2012



Risk factors for early onset severe community-acquired pneumonia complications
Source: International Congress 2018 – Pleural diseases and pneumonia: what's new ?
Year: 2018




Do admission glucose levels aid in predicting mortality associated with community-acquired pneumonia?
Source: Eur Respir J, 50 (4) 1700307; 10.1183/13993003.00307-2017
Year: 2017



Inflammatory responses predict long-term mortality risk in community-acquired pneumonia
Source: Eur Respir J 2011; 37: 1439-1446
Year: 2011



Biomarkers and cardiovascular events in community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016



Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 groups at risk
Source: Eur Respir J 2007; 30: Suppl. 51, 481s
Year: 2007

Systemic cytokine levels in community-acquired pneumonia and their association with disease severity
Source: Eur Respir J 2002; 20: 990-995
Year: 2002



Bacteremic pneumococcal pneumonia is associated with an increased rate of cardiovascular events
Source: International Congress 2019 – Pneumonia in 2019: antimicrobial resistance, cardiovascular complications and diagnosis
Year: 2019



3-day mortality in hospitalised community-acquired pneumonia: frequency and risk factors
Source: Eur Respir J 2016; 47:1572-1574
Year: 2016


Admission glucose concentrations independently predict early mortality in patients with community-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 482s
Year: 2007

Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011

The main risk factors of the community-acquired pneumonia delayed course
Source: Eur Respir J 2005; 26: Suppl. 49, 643s
Year: 2005

The post-tuberculosis lung changes as risk factor of the community-acquired pneumonia delayed course
Source: Eur Respir J 2006; 28: Suppl. 50, 351s
Year: 2006

Influence of chronic cardiovascular diseases (CVD) on course and outcome of community-acquired pneumonia (CAP)
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017

Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 42s
Year: 2007

Prediction of complications development and lethal outcome in patients with community-acquired pneumonia
Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura
Year: 2011